CLAIMS

1. A compound of Formula (V):



(V)

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is selected from the group consisting of:



;

R^2 is C_1 alkyl, C_3 alkyl, -(C_1 alkylene)-OH, or -(C_3 alkylene)-OH;

R^3 is selected from the group consisting of:





,


,


,


,


,


,


, and


;

R^4 is Cl or F;

R^5 is -(C_1 alkylene)-OH, or C_1 alkyl, or alternatively R^2 and R^5 are taken together to form a 7-membered heterocycloalkyl comprising one heteroatom O;

R^6 represents one or two substituents selected from the group consisting of H, -OH, halogen, -(C_1-C_6 alkylene)-OH, -CN, -(C_1-C_6 alkylene)-CN, C_1-C_6 alkyl, C_3-C_6 cycloalkyl, C_1-C_6 fluoroalkyl, C_3-C_6 fluorocycloalkyl, and C_1-C_6 alkoxy;

L is a linker comprising one, two or three members independently selected from the group consisting of -O-, -S-, -NR^7-, and -CR^8R^9-;

R^7, R^8, and R^9 are each independently H or C_1-C_3 alkyl;

X is O, N, or S; and

l is 1 or 2.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is selected from the group consisting of:



.

3. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R^1 is:



4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R^2 is C_3 alkyl, and R^5 is -(C_1 alkylene)-OH.

5. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R^2 is -(C_3 alkylene)-OH, and R^5 is C_1 alkyl.

6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^2 and R^5 are taken together to form a 7-membered heterocycloalkyl comprising one heteroatom O.

7. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R^2 and R^5 are taken together to form a 7-membered heterocycloalkyl comprising one heteroatom O.

8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R^3 is:



9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R^4 is F.

10. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein X is O, l is 1.

11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has Formula (VI):



(VI)

12. The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein R^2 is C_3 alkyl, and R^5 is -(C_1 alkylene)-OH.

13. The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein R^2 is -(C_3 alkylene)-OH, and R^5 is C_1 alkyl.

14. The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein R^2 and R^5 are taken together to form a 7-membered heterocycloalkyl comprising one heteroatom O.

15. A compound of Formula (VII)



(VII)

or a pharmaceutically acceptable salt thereof, wherein R^{11}, R^{12}, R^{13}, and R^{14} are each independently H or C_1-C_3 alkyl.

16. The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein R^{11}, R^{12}, R^{13}, and R^{14} are each independently H or methyl.

17. The compound of claim 15 or 16, or a pharmaceutically acceptable salt thereof, wherein the compound is



.

18. A compound or a pharmaceutically acceptable salt thereof, selected from the group consisting of:



,



,



,



,



,



,

and



.

19. A pharmaceutical composition comprising a compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

20. A compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, for use as a medicament.

21. A compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.

22. The compound for use according to claim 21, wherein the cancer is non-small cell lung cancer (NSCLC), pancreatic cancer, or colorectal cancer.

23. Use of a compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer.

24. The use of claim 23, wherein the cancer is non-small cell lung cancer (NSCLC), pancreatic cancer, or colorectal cancer.

25. Use of a compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disorder mediated by inhibition of KRAS G12C, KRAS G12D, and KRAS G12V receptors in a subject.

26. A pharmaceutical combination comprising a compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, and at least one additional therapeutic agent or a pharmaceutically acceptable salt thereof.

27. A pharmaceutical composition comprising the pharmaceutical combination of claim 26 and at least one excipient.